CRISPR Therapeutics to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference

ZUG, Switzerland and CAMBRIDGE, Mass., Nov. 24, 2020 (GLOBE NEWSWIRE) — CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference on Wednesday, December 2, 2020, at 9:30 a.m. ET.

A live webcast of the event will be available on the “Events & Presentations” page in the Investors section of the Company’s website at https://crisprtx.gcs-web.com/events. A replay of the webcast will be archived on the Company’s website for 14 days following the presentation.

About CRISPR Therapeutics

CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with leading companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.

CRISPR THERAPEUTICS® word mark and design logo are trademarks and registered trademarks of CRISPR Therapeutics AG. All other trademarks and registered trademarks are the property of their respective owners.

Investor Contact:
Susan Kim
+1-617-307-7503
susan.kim@crisprtx.com

Media Contact:
Rachel Eides
WCG on behalf of CRISPR
+1-617-337-4167
reides@wcgworld.com

 

Staff

Recent Posts

Humana Redefines the Member Experience with Agent Assist Built with Google Cloud

Humana introduces Agent Assist to help member advocates deliver faster, more personalized support, enabled by…

56 minutes ago

AssureCare Announces Parth Shah’s Promotion to Senior Vice President of Customer Success and Enterprise AI Delivery

CINCINNATI, Feb. 3, 2026 /PRNewswire/ -- AssureCare® LLC, a leading healthcare technology company delivering an…

56 minutes ago

Doxim Scales Utility Payments Team to Support Rapid Market Growth

Doxim's Utility Payments Team will drive seamless, omnichannel billing-to-payments solutions for utilities to bridge the…

56 minutes ago

Amplifire Recognized by Brandon Hall Group for Breakthrough AI Authoring Technology

BOULDER, Colo., Feb. 3, 2026 /PRNewswire/ -- Amplifire, the leading adaptive learning platform built on patented…

56 minutes ago

Cognision Launches Cognision360™: A Unified Platform Transforming Neurobiomarker Acquisition, Processing, and Analysis in CNS Clinical Trials

LOUISVILLE, Ky., Feb. 3, 2026 /PRNewswire/ -- Cognision today unveiled Cognision360™, a groundbreaking web-based platform that consolidates…

56 minutes ago